Zeitschriftenartikel: „Strophanthinum“

1

Shah, Yatin. „Strophanthin – ein besonderes Herzglykosid“. Zeitschrift für Komplementärmedizin 3, Nr. 02 (April 2011): 48–51. http://dx.doi.org/10.1055/s-0030-1270928.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Schmidramsi, H., B. Ostermayr und J. v. Arnim. „Proving of g-strophanthin“. British Homoeopathic journal 82, Nr. 4 (Oktober 1993): 269. http://dx.doi.org/10.1016/s0007-0785(05)80679-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Tsyvunin, V. V., S. Yu Shtrygol, D. V. Shtrygol und D. P. Kavraiskyi. „Anticonvulsive potential of cardiac glycosides under conditions of pentilentetrazole-induced seizures in mice: comparative study“. Acta Medica Leopoliensia 27, Nr. 1-2 (Juni 2021): 63–69. http://dx.doi.org/10.25040/aml2021.01-02.063.

Der volle Inhalt der Quelle

Annotation:

Aim. The research provides a comparative analysis of the possible anticonvulsant action of different cardiac glycosides, namely: digoxin, lanatoside C, strophanthin G and corglycone. In addition, it detrmines the leading medication among the abovementioned ones by dose-dependence of its anticonvulsant action. Material and Methods. The research was performed on 66 random-bred albino male mice. The anticonvulsant effect of cardiac glycosides was studied in a baseline model of pentylenetetrazole-induced seizures. The first series of experiment evaluated the effect of cardiac glycosides on the course of model seizures in comparable doses of approximately 1/10 LD50 for the corresponding drug: digoxin, lanatoside C and strophanthin G - at a dose of 0.8 mg/kg; corglycone - at a dose of 1 mg/kg. The second series of experiments used the drug-leader, which was digoxin, in a wide dose range from 0.2 to 1.6 mg/kg. Digoxin, strophanthin G and corglycone were administered subcutaneously for 15 minutes, lanatoside C - intragastrically for 30 minutes before the induction of experimental seizures. Convulsive agent - pentylenetetrazole in the form of an aqueous solution was administered to animals subcutaneously at a dose of 80 mg/kg. Results and Discussion. Digoxin at a dose of 0.8 mg/kg under conditions of pentylenetetrazole-induced seizures shows a pronounced anticonvulsant activity: it is the only one among the studied cardiac glycosides that probably reduces lethality. In addition, digoxin prolongs the latency period of the first attacks, and reduces the number of clonic-tonic paroxysms in 1 mouse. Moderate anticonvulsant properties of lanatoside C were found both by a statistically significant decrease in the number of clonic-tonic seizures in 1 mouse, and by a significant reduction in the duration of the convulsive period. Although strophanthin G is unlikely to affect lethality, it moderately reduces the severity of pentylenetetrazole-induced seizures in mice, as evidenced by a statistically significant prolongation of the latency period of the first seizures, as well as a decrease in the number of clonic-tonic seizures in 1 mouse and the duration of seizures. Prophylactic administration of corglycone only prolongs the latency period of seizures and significantly reduces the number of clonic-tonic seizures in 1 mouse. The results of the dose-dependence study of digoxin anticonvulsant action show a clear anticonvulsant potential of this cardiac glycoside in a wide range of doses - from 0.2 to 1.6 mg/kg - with a maximum effect at a dose of 0.8 mg/kg. Conclusions. It was found that cardiac glycosides have a different severity of anticonvulsant effect: the most powerful anticonvulsant effect is due to digoxin, lanatoside C and strophanthin G have moderate properties, and the least pronounced effect is characteristic to corglycone. In addition, it was determined that digoxin exhibits anticonvulsant properties in a wide range of doses, and has the most pronounced anticonvulsant effect at a dose of 0.8 mg/kg. The obtained results substantiate the expediency of further in-depth study of digoxin as an anticonvulsant medicine.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Vilensky, L. „Strofantin and novazurol for heart disease“. Kazan medical journal 20, Nr. 9 (11.08.2021): 990–91. http://dx.doi.org/10.17816/kazmj77072.

Der volle Inhalt der Quelle

Annotation:

Weiss (Deut, med Woch., 1924 No. 33) reports on his observations on the treatment of severe cardiac patients with strophanthin and novosurol. In chronic heart diseases in a state of sharp decompensation, sometimes digitalis has no effect, especially when the body, due to the prolonged use of small doses of digitalis, has become accustomed to this remedy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

McKenzie, A. G. „The rise and fall of strophanthin“. International Congress Series 1242 (Dezember 2002): 95–100. http://dx.doi.org/10.1016/s0531-5131(02)00729-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Dadashyan, A. M. „Experience in the use of convallotoxin in circulatory failure“. Kazan medical journal 43, Nr. 5 (16.11.2021): 52–53. http://dx.doi.org/10.17816/kazmj87787.

Der volle Inhalt der Quelle

Annotation:

In the domestic literature, there are very few works on the action of convallotoxin, but they testify to the great effectiveness of the drug in patients with cardiovascular insufficiency. KA Khasanov believes that the therapeutic effect of konvallotoxin is not inferior to strophanthin, has a pronounced vascular and sedentary effect. LI Zhukovsky and BM Klebanov, noting the positive effect of konvallotoxin, pay attention to its side effects (the occurrence of pain and a feeling of compression in the heart, palpitations, shortness of breath, headaches, etc.).

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Frost, Jørgen, und Erik Warburg. „Clinical experiences concerning the effect of strophanthin“. Acta Medica Scandinavica 130, S206 (24.04.2009): 132–44. http://dx.doi.org/10.1111/j.0954-6820.1948.tb12030.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Ionova, E. O., I. A. Miroshkina, A. V. Sorokina und S. A. Kryzhanovskii. „Comparative evaluation of echocardiographic and morphometric characteristics of the rat heart left ventricle“. Pharmacokinetics and Pharmacodynamics, Nr. 1 (10.05.2023): 41–44. http://dx.doi.org/10.37489/2587-7836-2023-1-41-44.

Der volle Inhalt der Quelle

Annotation:

Purpose of the study. Comparative evaluation of echocardiographic and morphometric dimensions of the rat heart left ventricle. Materials and methods. The study included 10 outbred male rats weighing 160–180 g. The size of the heart left ventricle was assessed using echocardiography and morphometry. The measurements were carried out according to standard protocols. To perform morphometric measurements, hearts were stopped in systole with a lethal dose (1.0 mg/kg) of 0.025 % strophanthin K solution, and in diastole, by immersing the hearts in a chilled physiological solution (calcium-free medium). Results. It was shown that the systolic size of the left ventricle of the heart according to echocardiography is 1.79Ѓ}0.10 mm, and morphometry 1.64Ѓ}0.09 mm (p = 0,302); diastolic size of the left ventricle, respectively, 3.42Ѓ}0.16 mm and 3.66Ѓ}0.17 mm (р = 0,318). The detected discrepancies do not exceed 10 % and, apparently, are due to the fact that the physiological dimensions of the heart left ventricle are measured by a non-invasive echocardiographic method, and for morphometric measurements of the dimensions in the systole, the heart was stopped by injection of strophanthin K, which entails an overload of heart cells with Ca2+ ions and as a result, contracture of cardiomyocytes; post-mortem cardiac arrest in diastole, in a calcium-free environment, is accompanied by a loss of cardiac muscle tone and, therefore, dilatation of the left ventricle will naturally be greater than physiological. Conclusion. Noninvasive echocardiographic measurement of the size of the heart left ventricle fully reflects the actual size of the left ventricle of the rat heart (the difference does not exceed 10 %), i. e. echocardiographic measurements are valid.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Grosa, Giorgio, Gianna Allegrone und Erika Del Grosso. „LC–ESI-MS/MS characterization of strophanthin-K“. Journal of Pharmaceutical and Biomedical Analysis 38, Nr. 1 (Juni 2005): 79–86. http://dx.doi.org/10.1016/j.jpba.2004.12.008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Olesin, A. I., I. V. Konstantinova, N. N. Tyuteleva und V. S. Ivanov. „Clinical and prognostic significance of left ventricular dysfunction predictors in patients with ventricular ectopy and without structural heart disease“. Fundamental and Clinical Medicine 8, Nr. 3 (29.09.2023): 53–67. http://dx.doi.org/10.23946/2500-0764-2023-8-3-53-67.

Der volle Inhalt der Quelle

Annotation:

Aim. To determine the predictors of left ventricular dysfunction in patients with ventricular ectopic beats without structural heart disease.Material and Methods. We modeled ventricular ectopy in rats through early afterdepolarization (aconitine-induced arrhythmia) and delayed afterdepolarization (adrenaline arrhythmia). In addition, we modeled ventricular ectopy in rabbits and cats by delayed afterdepolarization (barium chloride-induced and strophanthin arrhythmias, respectively) and also modeled ventricular ectopy in dogs by re-entry hydrogen peroxide-induced arrhythmia. In addition to conventional electrocardiography parameters, we analyzed pre-ectopic interval, its variability, and the internal deviation index. Further, the study included 514 patients aged 16 to 34 years (mean 21.2 ± 0.2 years), and the number of premature ventricular contractions (PVCs) per day of observation ranged from 6,157 to 37,254 (mean 19,706 ± 656 PVCs). We registered the same parameters as in experimental arrhythmias but calculated them separately for mono- and polymorphic, left and right ventricular out-flow tract arrhythmias. The duration of follow-up of patients was up to 10 years. The endpoint was the detection or absence of cardiovascular and/or extracardiac pathology.Results. We recorded polymorphic PVCs and early monomorphic PVCs when modeling ventricular arrhythmias by the mechanism of delayed post-depolarization and early post-depolarization, respectively. Both early and late monomorphic PVCs were documented when inducing ventricular arrhythmias by re-entry. When modeling hydrogen peroxide-induced and strophanthin arrhythmias, we observed significantly higher values of PVC-QRS complex and ventricular arrhythmia internal deviation index in comparison with aconitine-induced arrhythmia. Favourable outcome was registered in 50.97% of patients, whilst coronary artery disease, arterial hypertension, and mitral valve prolapse were documented in 7.98%, 16.73% and 2.92% patients. The rest of the patients had gastrointestinal diseases. In patients with favourable outcome, the signs of monomorphic PVCs correlated with those revealed during the modeling of ventricular ectopy by early afterdepolarization (r = 0.92), whereas those signs of polymorphic PVCs correlated with those observed at barium chloride-induced delayed afterdepolarization (r = 0.94). In patients with CAD, signs of PVCs correlated with those registered during re-entry hydrogen peroxide-induced arrhythmia (r = 0.93), Finally, in patients with arterial hypertension and mitral valve prolapse signs of PVCs correlated with those documented at strophanthin-(r = 0.92) and adrenaline-induced delayed afterdepolarization (r = 0.89). In these patients, the values for both monomorphic and polymorphic PVCs, ventricular arrhythmia internal deviation index, duration of PVC-QRS complex and PVC-QRS/QRSaverage did not exceed 0.42 units, 149 ms and 1,44 units, respectively. The development of coronary artery disease and arterial hypertension well correlated with an increase in ventricular arrhythmia internal deviation index ≥ 0.56 units and QRS complex duration ≥ 157 ms. Mitral valve prolapse was associated with the duration of the QRS complex ≥ 159 ms of polymorphic PVCs.Conclusion. In patients with ventricular ectopy but without structural heart disease, an increase in the values of ventricular arrhythmia internal deviation index and the duration of PVC-QRS complex was ≥ 0.48 units and 149 ms, respectively, associated with the development of cardiovascular pathology. Development of coronary artery disease and hypertension correlated with ventricular arrhythmia internal deviation index ≥ 0.56 units, and QRS complex duration ≥ 157 ms in monomorphic and polymorphic PVCs, whereas development of mitral valve prolapse correlated QRS complex duration ≥ 159 ms in polymorphic PVCs.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Arnim, H. Schmidramsl; B. Ostermayr; J. v. „g-Strophanthin - Ergebnisse von 2 Arzneimittelprüfungen mit der 4. Dezimalpotenz“. Allgemeine Homöopathische Zeitung 238, Nr. 03 (04.04.2007): 106–9. http://dx.doi.org/10.1055/s-2006-936451.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Chekman, I. S., N. A. Gorchakova, V. V. Bratus' und I. S. Mudraya. „Combined inotropic effect of strophanthin and calcium on heart muscle“. Bulletin of Experimental Biology and Medicine 99, Nr. 3 (März 1985): 317–20. http://dx.doi.org/10.1007/bf00799077.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Galenko-Yaroshevskii, P. A., S. M. Lemkina und Ya V. Kostin. „Drug correction of impaired strophanthin tolerance during simulated cardiac decompensation“. Bulletin of Experimental Biology and Medicine 117, Nr. 5 (Mai 1994): 483–86. http://dx.doi.org/10.1007/bf02444295.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Bogus, Saida K., Pavel A. Galenko-Yaroshevsky, Konstantin F. Suzdalev, Galina V. Sukoyan und Valery G. Abushkevich. „2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1 H-indole hydrochloride (SS-68): Antiarrhythmic and cardioprotective activity and its molecular mechanisms of action (Part I)“. Research Results in Pharmacology 4, Nr. 1 (31.08.2018): 130–55. http://dx.doi.org/10.3897/rrpharmacology.4.28592.

Der volle Inhalt der Quelle

Annotation:

Introduction. The problem of heart rhythm disturbances is one of the most urgent topics of modern cardiology. According to the currently available concepts, 1,2- and 1,3-disubstituted aminoindole derivatives, which compound 2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1H-indole hydrochloride (SS-68) belongs to, are a promising chemical group in terms of their cardio-pharmacological activity. Materials and methods. To study the anti-arrhythmic activity of SS-68 compound, the following models were used: 1) Models of cardiogenic arrhythmia: aconitine-inducedic, calcium chloride-induced, barium chloride-induced, cesium chloride-induced, adrenaline model of arrhythmia, strophanthine-induced arrhythmias, as well as arrhythmias caused by electrostimulation and acute myocardial ischemia; 2) neurogenic arrhythmias: arrhythmias caused by administration of aconitine, strophanthine K, cesium chloride into the IV ventricle of the brain and also by applying carbachol on the somatosensory cortex. To assess the antianginal activity of SS-68 in various models, the effect of this drug and comparators on the intact and ischemic myocardium was studied. Results. It was found that with cardiogenic arrhythmias, SS-68 compound exhibits a pronounced antiarrhythmic effect and brings to normal the electrophysiological pattern of the heart, in most cases exceeding the analogous effect of reference drugs (amiodarone, lidocaine, aymaline, ethacizine, etmozine, quinidine anaprilin). In neurogenic arrhythmias, SS-68 also had a stopping effect, and, in addition, reduced the epileptiform activity of the brain in the model with the application of carbachol on the somatosensory cortex. In the study of antianginal and coronary vasolidating activities, SS-68 demonstrated pronounced thrombolytic and anti-ischemic activities, manifested in an increase in the coronary blood flow, a positive effect on ST-segment depression, and a decrease in the area of necrosis in experimental myocardial infarction. Discussion. The antiarrhythmic and antianginal activities of SS-68 compound create the prerequisites for further study of the pharmacological properties of this molecule. In addition, it seems appropriate to continue studying the pharmacodynamics, pharmacokinetics and molecular mechanisms of SS-68 action. Conclusions. SS-68 compound is a promising pharmacological agent with a high activity towards various electrophysiological disorders in the heart, and, in addition, it has significant antiischemic and coronary vasolidating properties.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Tawfik, Hoda, Alanna A. L. Fox und Kurt Greeff. „Comparative studies of some semisynthetic K-strophanthins with natural cardiac glycosides“. Biochemical Pharmacology 34, Nr. 14 (Juli 1985): 2541–47. http://dx.doi.org/10.1016/0006-2952(85)90540-4.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Karsanov, N. V., G. V. Sukoyan, D. R. Tatulashvili, V. N. Karsanov und L. D. Mamulashvili. „Difference between mechanisms of action ofβ-acetyldigoxin, strophanthin K, and ouabain“. Bulletin of Experimental Biology and Medicine 113, Nr. 2 (Februar 1992): 186–89. http://dx.doi.org/10.1007/bf00791495.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Krupin, Theodore, Lisa F. Rosenberg, Arnold L. Sandridge, Charles J. Bock, Adrienne Berman und Jon M. Ruderman. „Effects of Topical K-Strophanthin on Aqueous Humor and Corneal Dynamics“. Journal of Glaucoma 4, Nr. 5 (Oktober 1995): 327???333. http://dx.doi.org/10.1097/00061198-199510000-00006.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

ZENG, YONG-CHUN, ZHENG-JUN JIN und PEI-KUN GU. „Retinal Toxicity in Albino Rabbits Induced by Intravitreal Injection of Strophanthin-K“. Journal of Ocular Pharmacology and Therapeutics 6, Nr. 1 (Januar 1990): 51–60. http://dx.doi.org/10.1089/jop.1990.6.51.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Sobieva, Z. I., M. N. Karpova und E. G. Kryzhanovskaya. „Effect of lithium compounds on cardiac arrhythmias induced by strophanthin in conscious rats“. Bulletin of Experimental Biology and Medicine 99, Nr. 4 (April 1985): 410–13. http://dx.doi.org/10.1007/bf00842725.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Kudryavtseva, N. P., V. I. Kachurets und S. X. Nasibullina. „The use of strophanthin in the complex treatment of cardiovascular disorders in toxic diphtheria“. Kazan medical journal 43, Nr. 3 (29.10.2021): 42–43. http://dx.doi.org/10.17816/kazmj83692.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

ÖSTLING, GUSTAF. „The Significance of the Speed of Injection for the Therapeutic Effect of K-Strophanthin“. Acta Medica Scandinavica 129, Nr. 1 (24.04.2009): 77–80. http://dx.doi.org/10.1111/j.0954-6820.1947.tb09286.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Guang-tian, Yang, und S. Daum. „Wirkung von Strophanthin, Digoxin und Isoproterenol auf die Herzkontraktilität während Hypoxie und hyperkapnischer Azidose“. Journal of Tongji Medical University 6, Nr. 4 (Dezember 1986): 199–205. http://dx.doi.org/10.1007/bf02909745.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Sergeev, P. V., P. A. Galenko-Yaroshevskii, S. M. Lemkina und Ya V. Kostin. „Comparative evaluation of pharmacological effects of combined application of strophanthin with some antiadrenergic agents“. Bulletin of Experimental Biology and Medicine 119, Nr. 5 (Mai 1995): 484–87. http://dx.doi.org/10.1007/bf02543436.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Pogorelova, V. N., A. I. Panait und A. G. Pogorelov. „Nonspecific effect of Na+/K+-ATPase inhibition with strophanthin or under hypothermia in rat heart“. Biophysics 59, Nr. 5 (September 2014): 768–71. http://dx.doi.org/10.1134/s0006350914050212.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Rajabzoda, M. M. „Consequences of road transportation accidents, their standard growth, modern management and tactics of treatment of victims“. Health care of Tajikistan, Nr. 2 (21.07.2022): 82–87. http://dx.doi.org/10.52888/0514-2515-2022-353-2-83-88.

Der volle Inhalt der Quelle

Annotation:

Aim. Improvement of the results of diagnostics and provision of pre- and hospital medical care to victims with concomitant and multiple trauma in road accidents. Material and research methods. Based on the analysis of the results of diagnosis and treatment, it was found that the Department of Traumatology and Orthopedics of the Regional Clinical Hospital named after B. Vohidov of the city of Bokhtar (former Kurgan-Tyube) for the period 2012 - 2020. there were 2120 patients with injuries. 1234 (58.2 %) victims were injured as a result of road accidents. Research results and their discussion. Prehospital care for victims with concomitant and multiple trauma:1) Pain relief through the use of non-narcotic and narcotic analgesics, aseptic dressings on wounds;2) Immobilizing position of the victim on the shield and stretcher for transportation;3) Introduction of cardiac and respiratory analeptics (strophanthin, korglikon, cordiamine); Conclusion. Thus, in the provision of emergency care to patients with concomitant and multiple trauma on the background of road traffic accidents, the following seems justified.1. Constantly train traffic police officers, drivers of passenger vehicles in the methods of providing first aid directly at the scene of the accident.2. Strengthen the personnel and material - technical potential of regional hospitals located on the highway.3. Improvement of diagnostic and treatment algorithms, training, regular discussion of tactical guidelines their possible correction.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Bauer, N., G. Scheiner-Bobis und W. Schoner. „„Endogenes Digitalis” – der lange Weg vom herzwirksamen pflanzlichen Toxin zum Hormon der Säuger“. Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere 34, Nr. 06 (2006): 389–97. http://dx.doi.org/10.1055/s-0037-1622553.

Der volle Inhalt der Quelle

Annotation:

ZusammenfassungEndogene Herzglykoside wurden kürzlich aus Blut, Urin, Nebennieren und Hypothalamus von Säugetieren isoliert und in ihrer Struktur aufgeklärt. Zu den endogenen Herzglykosiden zählen so gut bekannte Hemmstoffe der Natriumpumpe wie Ouabain (g-Strophanthin), Digoxin und Marinobufagenin. Endogenes Ouabain und Digoxin werden in der Nebennierenrinde der Säuger aus Progesteron und Pregnenolon synthetisiert. Ouabain wird bei Kreislaufbelastung rasch freigesetzt, seine Konzentration fällt bei Ruhe innerhalb weniger Minuten wieder ab. ACEInhibitoren und β-Blocker verhindern bei Hunden diesen Anstieg. Ouabain wird durch ACTH, Adrenalin und Angiotensin II aus Nebennierenrindenzellen in Kultur freigesetzt. Nanomolare Ouabain-Konzentrationen stimulieren die Proliferation von glatten Muskelzellen. An schwerer dilatativer Kardiomyopathie erkrankte Hunde haben im Vergleich zu gesunden Hunden signifikant erniedrigte Ouabain-Blutwerte. Beim Menschen und Ratten führt eine lang dauernde zu hohe NaCl-Zufuhr über die Nahrung zum Konzentrationsanstieg von endogenem Ouabain im Blut und zum Bluthochdruck. Eine über lange Zeit durchgeführte Infusion von Ouabain, aber nicht von Digoxin, erzeugt bei Ratten Bluthochdruck. Digoxin senkt den Ouabain-induzierten Bluthochdruck. Da bei ca. 50% der Hochdruckpatienten erhöhte Ouabain-Werte vorliegen, ist es von großer medizinischer Bedeutung, dass mit dem Ouabain-Antagonisten Rostafuroxin ein neues Prinzip und eine neue Gruppe von Blutdrucksenkern gefunden wurde. Marinobufagenin, dessen Konzentration bei Herzinfarkt akut ansteigt, hat auf die Niere eine natriuretische Wirkung. Im Gehirn wird Ouabain im Hypothalamus synthetisiert und bei einer erhöhten intrazellulären Natriumkonzentration freigesetzt.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Sørensen, Else Vigholt, und Folmer Nielsen-Kudsk. „Single and combined myocardial pharmacodynamics of xamoterol, isoprenaline and g-strophanthin in the isolated rabbit heart“. European Journal of Pharmacology 125, Nr. 3 (Juni 1986): 363–71. http://dx.doi.org/10.1016/0014-2999(86)90792-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Mikhailov, I. B. „Effect of strophanthin and digoxin on activity of an experimental epileptogenic focus in the frog hippocampus“. Bulletin of Experimental Biology and Medicine 104, Nr. 5 (November 1987): 1572–74. http://dx.doi.org/10.1007/bf00845084.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Fazulzyanov, A. A., V. M. Andreev und G. N. Fazulzyanova. „Respiratory mechanics, alveolar ventilation, ventilation-perfusion relations in the correction of heart failure with strophanthin and kapoten“. Kazan medical journal 76, Nr. 6 (15.11.1995): 417–19. http://dx.doi.org/10.17816/kazmj90429.

Der volle Inhalt der Quelle

Annotation:

In patients with chronic heart failure due to chronic heart disease (rheumatic heart disease, hypertension, coronary artery disease with postinfarction and atherosclerotic cardiosclerosis), changes in pulmonary hemodynamics contribute to the development of respiratory failure.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Bonah, Christian. „‘The Strophanthin question’: early scientific marketing of cardiac drugs in two national markets (France and Germany, 1900–1930)“. History and Technology 29, Nr. 2 (Juni 2013): 135–52. http://dx.doi.org/10.1080/07341512.2013.833039.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Hassan, A. B., M. Atef und I. M. Shihata. „Effect of Digoxin and Strophanthin on Renal Blood Flow and Systemic Blood Pressure in Normal and Bled Dogs“. Zentralblatt für Veterinärmedizin Reihe A 26, Nr. 2 (13.05.2010): 152–58. http://dx.doi.org/10.1111/j.1439-0442.1979.tb00660.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Galenko-Yaroshevskii, P. A., S. M. Lemkina und Ya V. Kostin. „Effects of the membrane stabilizer ajmaline and the local anesthetic trimecaine on the pharmacological effects of strophanthinin vivo andin vitro“. Bulletin of Experimental Biology and Medicine 117, Nr. 1 (Januar 1994): 61–64. http://dx.doi.org/10.1007/bf02444082.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Karsanov, N. V., T. N. Macharashvili und V. A. Magaldadze. „Action of strophanthin K and ?-acetyldigoxin in vitro on energy transformation by the contractile protein system of normal cardiomyocytes“. Bulletin of Experimental Biology and Medicine 108, Nr. 6 (Dezember 1989): 1735–38. http://dx.doi.org/10.1007/bf00841047.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Galenko-Yaroshevskii, P. A., S. M. Lernkina und Ya V. Kostin. „Correction with cordarone of changes in cathepsin D activity induced by modeled circulation insufficiency and toxic action of strophanthin K“. Bulletin of Experimental Biology and Medicine 122, Nr. 4 (Oktober 1996): 1005–7. http://dx.doi.org/10.1007/bf02447021.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Galenko-Yaroshevskii, P. A., S. M. Lemkina und Ya V. Kostin. „Correction of altered β-glucosidase activity induced by the toxic effect of strophanthin K and modeled cardiac decompensation with cordaron“. Bulletin of Experimental Biology and Medicine 121, Nr. 6 (Juni 1996): 581–83. http://dx.doi.org/10.1007/bf02447123.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Karsanov, N. V., V. A. Magaldadze und T. N. Macharashvili. „Action of strophanthin K and ?-acetyldigoxin in vitro on energy transformation by the myocardial contractile protein system in toxico-allergic cardiomyopathy“. Bulletin of Experimental Biology and Medicine 111, Nr. 5 (Mai 1991): 698–700. http://dx.doi.org/10.1007/bf00841022.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Agostoni, Pier Giuseppe, Elisabetta Doria, Marco Berti und Maurizio D. Guazzi. „Long-term use of K-strophanthin in advanced congestive heart failure due to dilated cardiomyopathy: A double-blind crossover evaluation versus digoxin“. Clinical Cardiology 17, Nr. 10 (Oktober 1994): 536–41. http://dx.doi.org/10.1002/clc.4960171005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Krvavych, Anna, und Roksolana Konechna. „Optimization of parameters of the extraction process of biologically active substances of grass Adonis vernalis“. Technology audit and production reserves 3, Nr. 3(59) (02.07.2021): 14–18. http://dx.doi.org/10.15587/2706-5448.2021.235471.

Der volle Inhalt der Quelle

Annotation:

The object of this research is the herb Adonis vernalis and hydroalcoholic extracts obtained on its basis. By the nature of the action, the drugs Adonis vernalis belong to the group of cardiac glycosides and occupy an intermediate place between strophanthin and digitalis. In official medicine, biologically active compounds of Adonis vernalis are included in drugs such as Cardiovalen, Adonis-bromine, Caridiolin and Cardiophyte. In the extemporal formulation, the extract is part of the Bechterew’s medicine. Until recently, scientists have made significant progress in studying the phytochemical and pharmacological action of the herb Adonis vernalis. However, one should not be limited to the use of Adonis vernalis only for stimulating cardiac activity, one should also consider the promising antioxidant effect of flavonoids and phenolic compounds that are contained in this medicinal plant. Also, studies of the extraction conditions of the herb Adonis vernalis are not described in the scientific literature. The study carried out the extraction of the grass Adonis vernalis by various methods (static and dynamic). The type of extract was chosen as the most rational, which provides the maximum yield of extractives (phenolic compounds and cardiac glycosides). For this, the optimal extraction conditions were selected, namely, the particle size, the type of extractant, the value of the hydromodule and the extraction method. Accordingly, the optimal particle diameter for maximum extraction of biologically active substances of the herb Adonis vernalis is 2.5 mm, the optimal extractant is 70 % ethyl alcohol, the ratio of raw materials: extractant is 1:10, the optimal extraction method is maceration with constant stirring. Phytochemical studies of the quantitative composition of the main groups of biologically active substances were carried out using calorimetric and spectrophotometric methods of analysis. As a result of the optimization of the process and its introduction into production on an industrial scale, the value added effect will be achieved. And also a high-quality product has been created that will compete with broad-spectrum drugs already existing on the market.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Galust'yan, G. �., und I. B. Mikhailov. „Effect of strophanthin and digoxin on succinate and lactate dehydrogenase and membrane Na+, K+-ATPase activity in the heart of rats with experimental myocarditis“. Bulletin of Experimental Biology and Medicine 107, Nr. 4 (April 1989): 498–500. http://dx.doi.org/10.1007/bf00842388.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Danielopolu, D., Marin Popescu und Gr Gr Popa. „Action of Drugs on Cholinesterase and on the Adrenolytic Factors. Inactivating Action of Eserine, Strophanthin and Ascorbic Acid on Cholinesterase and on the Adrenolytic Factors.“ Acta Pharmacologica et Toxicologica 4, Nr. 3-4 (13.03.2009): 339–50. http://dx.doi.org/10.1111/j.1600-0773.1948.tb03356.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Datté, J. Y., und A. Ziegler. „Pharmacological investigation on nigrescigenin-a cardenolide fromParquetina nigrescens(Afzel.) Bullock: comparative studies on cardiotonic effects ofParquetina nigrescens, g-strophanthin and noradrenaline in guinea-pig isolated atria“. Journal of Pharmacy and Pharmacology 53, Nr. 6 (Juni 2001): 859–66. http://dx.doi.org/10.1211/0022357011776018.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Sugimoto, Jiro, Seiichi Yuasa und Masayasu Suzuki. „Comparison of Effects of Alprenolol, Carteolol, Indenolol, Pindolol, Practolol, and Propranolol in Relation to their Beta-Blocking, Local Anaesthetic, Membrane Stabilizing, and Strophanthin-G Cardiotoxicity Antagonizing Actions in Guinea-Pig“. Journal of Kansai Medical University 39, Nr. 4 (1987): 418–29. http://dx.doi.org/10.5361/jkmu1956.39.4_418.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Doepp, Manfred. „May Strophanthin be a valuable cardiac drug ?“ American Journal of Medical and Clinical Research & Reviews 02, Nr. 09 (2023). http://dx.doi.org/10.58372/2835-6276.1069.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

„Die Lösung des Herzinfarkt-Problems durch g-Strophanthin“. Erfahrungsheilkunde 53, Nr. 02 (Februar 2004): 65–73. http://dx.doi.org/10.1055/s-2004-819994.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Sharma, Ashish Kumar, Shivam Singh, Mehvish Bhat, Kartik Gill, Mohammad Zaid, Sachin Kumar, Anjali Shakya et al. „New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models“. Scientific Reports 13, Nr. 1 (29.09.2023). http://dx.doi.org/10.1038/s41598-023-41942-4.

Der volle Inhalt der Quelle

Annotation:

AbstractCardiac rhythm regulated by micro-macroscopic structures of heart. Pacemaker abnormalities or disruptions in electrical conduction, lead to arrhythmic disorders may be benign, typical, threatening, ultimately fatal, occurs in clinical practice, patients on digitalis, anaesthesia or acute myocardial infarction. Both traditional and genetic animal models are: In-vitro: Isolated ventricular Myocytes, Guinea pig papillary muscles, Patch-Clamp Experiments, Porcine Atrial Myocytes, Guinea pig ventricular myocytes, Guinea pig papillary muscle: action potential and refractory period, Langendorff technique, Arrhythmia by acetylcholine or potassium. Acquired arrhythmia disorders: Transverse Aortic Constriction, Myocardial Ischemia, Complete Heart Block and AV Node Ablation, Chronic Tachypacing, Inflammation, Metabolic and Drug-Induced Arrhythmia. In-Vivo: Chemically induced arrhythmia: Aconitine antagonism, Digoxin-induced arrhythmia, Strophanthin/ouabain-induced arrhythmia, Adrenaline-induced arrhythmia, and Calcium-induced arrhythmia. Electrically induced arrhythmia: Ventricular fibrillation electrical threshold, Arrhythmia through programmed electrical stimulation, sudden coronary death in dogs, Exercise ventricular fibrillation. Genetic Arrhythmia: Channelopathies, Calcium Release Deficiency Syndrome, Long QT Syndrome, Short QT Syndrome, Brugada Syndrome. Genetic with Structural Heart Disease: Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Atrial Fibrillation, Sick Sinus Syndrome, Atrioventricular Block, Preexcitation Syndrome. Arrhythmia in Pluripotent Stem Cell Cardiomyocytes. Conclusion: Both traditional and genetic, experimental models of cardiac arrhythmias’ characteristics and significance help in development of new antiarrhythmic drugs.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Zeitschriftenartikel zum Thema „Strophanthinum“

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an